Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

USFDA issues 3 observations for Aurobindo Pharma’s Unit XI

The company has responded to the warning letter and carried out the committed corrections.

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study

The NTM-001 Phase I clinical study is expected to be completed by the end of 2022

Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration

Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's

Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million